dc.contributor
Institut Català de la Salut
dc.contributor
[Champiat S] Gustave Roussy, Departement d’Innovation Therapeutique et d’Essais Precoces (DITEP), Universite Paris Saclay, Villejuif, France. Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [Garralda E, Galvao V] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Cassier PA] Department of Medical Oncology, Centre Leon Berard, Lyon, France. [Gomez-Roca C, Korakis I] Institut Universitaire du Cancer de Toulouse, Toulouse, France
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
CASSIER, Philippe
dc.contributor.author
Gomez-Roca, Carlos
dc.contributor.author
Korakis, Iphigenie
dc.contributor.author
Champiat, Stephane
dc.contributor.author
GARRALDA, Elena
dc.contributor.author
Galvao, Vladimir
dc.date.accessioned
2025-10-25T05:36:59Z
dc.date.available
2025-10-25T05:36:59Z
dc.date.issued
2025-04-25T09:38:10Z
dc.date.issued
2025-04-25T09:38:10Z
dc.date.issued
2025-02-18
dc.identifier
Champiat S, Garralda E, Galvao V, Cassier PA, Gomez-Roca C, Korakis I, et al. Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell Reports Med. 2025 Feb 18;6(2):101967.
dc.identifier
http://hdl.handle.net/11351/12989
dc.identifier
10.1016/j.xcrm.2025.101967
dc.identifier
001432748100001
dc.identifier.uri
http://hdl.handle.net/11351/12989
dc.description.abstract
Anti-tumor efficacy; Pembrolizumab combination; Solid tumors
dc.description.abstract
Eficacia antitumoral; Combinación de pembrolizumab; Tumores sólidos
dc.description.abstract
Eficàcia antitumoral; Combinació de pembrolizumab; Tumors sòlids
dc.description.abstract
Nanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor βγ superagonist that stimulates natural killer (NK) and CD8+ T cells, thereby promoting an innate and adaptive anti-tumor inflammatory microenvironment in mouse tumor models either in monotherapy or combined with an anti-programmed cell death protein 1 (PD-1) antibody. In cynomolgus monkeys, a clinical schedule was identified, which translated into the design of a phase 1/1b clinical trial, AURELIO-03 (NCT04234113). In 51 patients with advanced/metastatic solid tumors, nanril increased the proportions of CD8+ T cells and NK cells in peripheral blood and tumors. It had a favorable safety profile when administered subcutaneously on days 1, 2, 8, and 9 of each 21-day cycle as monotherapy (0.25–15 μg/kg) or combined (1.5–12 μg/kg) with the anti-PD-1 pembrolizumab (200 mg). The most frequent treatment-emergent adverse events were pyrexia, injection site reactions, and chills. Furthermore, early clinical efficacy was observed, including in immune checkpoint blockade-resistant/refractory patients.
dc.description.abstract
This study was funded by SOTIO Biotech AG.
dc.format
application/pdf
dc.relation
Cell Reports Medicine;6(2)
dc.relation
https://doi.org/10.1016/j.xcrm.2025.101967
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Càncer - Tractament
dc.subject
Cèl·lules K - Immunologia
dc.subject
Anticossos monoclonals - Ús terapèutic
dc.subject
Receptors cel·lulars
dc.subject
Animals de laboratori
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Costimulatory and Inhibitory T-Cell Receptors::Programmed Cell Death 1 Receptor
dc.subject
DISEASES::Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Killer Cells, Natural
dc.subject
Other subheadings::Other subheadings::Other subheadings::/immunology
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores inhibidores y coestimuladores de células T::receptor 1 de la muerte celular programada
dc.subject
ENFERMEDADES::neoplasias
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::células asesinas naturales
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/inmunología
dc.title
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
